JP2011518546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518546A5 JP2011518546A5 JP2011502087A JP2011502087A JP2011518546A5 JP 2011518546 A5 JP2011518546 A5 JP 2011518546A5 JP 2011502087 A JP2011502087 A JP 2011502087A JP 2011502087 A JP2011502087 A JP 2011502087A JP 2011518546 A5 JP2011518546 A5 JP 2011518546A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- pdgfr
- bispecific antibody
- residues
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 12
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4006808P | 2008-03-27 | 2008-03-27 | |
| US61/040,068 | 2008-03-27 | ||
| US14454709P | 2009-01-14 | 2009-01-14 | |
| US61/144,547 | 2009-01-14 | ||
| PCT/US2009/038495 WO2009120922A2 (en) | 2008-03-27 | 2009-03-27 | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013244129A Division JP5855627B2 (ja) | 2008-03-27 | 2013-11-26 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518546A JP2011518546A (ja) | 2011-06-30 |
| JP2011518546A5 true JP2011518546A5 (enExample) | 2012-11-01 |
| JP5425180B2 JP5425180B2 (ja) | 2014-02-26 |
Family
ID=40793092
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502087A Expired - Fee Related JP5425180B2 (ja) | 2008-03-27 | 2009-03-27 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
| JP2013244129A Expired - Fee Related JP5855627B2 (ja) | 2008-03-27 | 2013-11-26 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
| JP2015240210A Expired - Fee Related JP6140796B2 (ja) | 2008-03-27 | 2015-12-09 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013244129A Expired - Fee Related JP5855627B2 (ja) | 2008-03-27 | 2013-11-26 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
| JP2015240210A Expired - Fee Related JP6140796B2 (ja) | 2008-03-27 | 2015-12-09 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9441034B2 (enExample) |
| EP (3) | EP2604280A3 (enExample) |
| JP (3) | JP5425180B2 (enExample) |
| AU (3) | AU2009228158B2 (enExample) |
| CA (1) | CA2716882A1 (enExample) |
| CY (1) | CY1115382T1 (enExample) |
| DK (1) | DK2274008T3 (enExample) |
| ES (1) | ES2456296T3 (enExample) |
| HR (1) | HRP20140244T1 (enExample) |
| IL (3) | IL207618A (enExample) |
| PL (1) | PL2274008T3 (enExample) |
| PT (1) | PT2274008E (enExample) |
| SI (1) | SI2274008T1 (enExample) |
| WO (1) | WO2009120922A2 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| MX2011009810A (es) * | 2009-03-27 | 2011-09-30 | Zymogenetics Inc | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. |
| SG10201505593VA (en) | 2010-07-19 | 2015-09-29 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| JP2013538338A (ja) | 2010-07-19 | 2013-10-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌治療への応答可能性の増大した患者を同定する方法 |
| LT2647707T (lt) * | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| WO2013006244A1 (en) * | 2011-06-08 | 2013-01-10 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Bispecific monoclonal antibody therapeutics against west nile virus with improved cns penetration |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
| CA2857721C (en) * | 2011-12-05 | 2022-05-31 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
| SG11201405468QA (en) * | 2012-03-14 | 2014-10-30 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2014034735A1 (ja) * | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Vegf及び/又はアンギオポエチン-2の特異的エピトープを含むdnaワクチン |
| JP6590694B2 (ja) * | 2012-08-31 | 2019-10-16 | ザ スクリプス リサーチ インスティテュート | 真核生物細胞の調節因子に関する方法及び組成物 |
| US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| HUE060464T2 (hu) | 2013-03-13 | 2023-03-28 | Genzyme Corp | PDGF- és VEGF-kötõrészeket tartalmazó fúziós fehérjék és eljárások azok alkalmazására |
| CN104341504B (zh) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
| LT3065774T (lt) | 2013-11-06 | 2021-09-10 | Janssen Biotech, Inc. | Anti-ccl17 antikūnai |
| CN105263521B (zh) | 2014-01-15 | 2021-06-29 | 卡德门企业有限公司 | 免疫调节剂 |
| US10982221B2 (en) | 2014-01-27 | 2021-04-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection |
| MX380176B (es) | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| DK3151921T3 (da) | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf |
| US10519234B2 (en) * | 2014-06-27 | 2019-12-31 | Innate Pharma | NKp46 binding proteins |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
| AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| CA2980385A1 (en) | 2015-03-20 | 2016-09-29 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Pericyte long non-coding rnas |
| CN107743586B (zh) | 2015-06-03 | 2021-07-02 | 百时美施贵宝公司 | 用于癌症诊断的抗gitr抗体 |
| KR20180025865A (ko) | 2015-07-06 | 2018-03-09 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이적 항원 결합 분자 및 이의 용도 |
| AU2016307943A1 (en) * | 2015-08-14 | 2018-02-15 | Allergan, Inc. | Heavy chain only antibodies to PDGF |
| TWI799366B (zh) * | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
| MX2018005135A (es) * | 2015-10-30 | 2018-06-06 | Lilly Co Eli | Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos. |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| PL3389636T3 (pl) | 2015-12-16 | 2022-11-28 | Regeneron Pharmaceuticals, Inc. | Kompozycje i metody wytwarzania mikrocząstek białkowych |
| WO2017106609A2 (en) * | 2015-12-16 | 2017-06-22 | Kadmon Corporation, Llc. | Pdgfr beta antibody |
| JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Fc領域含有ポリペプチドの精製を効率化するための方法 |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| EP3431102A4 (en) | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| RU2656160C2 (ru) | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| JP6949106B2 (ja) * | 2016-08-23 | 2021-10-13 | メディミューン リミテッド | 抗vegf−a抗体ならびにそれらの使用 |
| US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Pd−1結合タンパク質を使用して白斑を治療する方法 |
| MY201744A (en) * | 2016-12-23 | 2024-03-15 | Visterra Inc | Binding polypeptides and methods of making the same |
| KR101908330B1 (ko) * | 2017-02-17 | 2018-10-16 | 인제대학교 산학협력단 | 신규 항-vegf 항체 및 이를 유효성분으로 포함하는 나이관련 황반변성 예방 또는 치료용 조성물 |
| US20180289802A1 (en) * | 2017-03-29 | 2018-10-11 | Celgene Corporation | Formulations comprising pd-1 binding proteins and methods of making thereof |
| JP6911490B2 (ja) * | 2017-04-26 | 2021-07-28 | 東ソー株式会社 | 安定型Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤 |
| JP7274426B2 (ja) | 2017-05-16 | 2023-05-16 | ブリストル-マイヤーズ スクイブ カンパニー | 抗gitrアゴニスト抗体での癌の処置 |
| CN109022415B (zh) * | 2017-06-12 | 2023-09-15 | 上海睿智化学研究有限公司 | PDGFRβ单克隆重链抗体杂交瘤细胞及其制备方法和应用 |
| BR112020003459A2 (pt) * | 2017-08-21 | 2020-08-25 | Adagene Inc. | bibliotecas, animal não humano, fago, cadeia leve de anticorpo, anticorpos, métodos para preparar uma biblioteca, para produzir uma biblioteca de anticorpos e para gerar um anticorpo biespecífico e kit |
| KR20200038996A (ko) | 2017-08-21 | 2020-04-14 | 아다진 인크. | 동적 인간 중쇄 항체 라이브러리 |
| TW201930351A (zh) * | 2017-10-06 | 2019-08-01 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| CN108094772A (zh) * | 2017-12-08 | 2018-06-01 | 桂林莱茵生物科技股份有限公司 | 一种罗汉果果汁及其制备方法 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| MA53293A (fr) * | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| NZ772550A (en) | 2018-08-30 | 2025-08-29 | Immunitybio Inc | Multi-chain chimeric polypeptides and uses thereof |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| CN112888445B (zh) | 2018-08-30 | 2025-06-10 | 免疫生物公司 | 治疗老年化相关病症的方法 |
| BR112021006352A2 (pt) | 2018-10-05 | 2021-07-06 | Univ Ewha Ind Collaboration | anticorpo receptor de pdgf e uso do mesmo |
| PE20211867A1 (es) | 2018-11-01 | 2021-09-21 | Shandong New Time Pharmaceutical Co Ltd | Anticuerpos biespecificos y su uso |
| KR20220035394A (ko) | 2019-06-21 | 2022-03-22 | 에이치씨더블유 바이올로직스, 인크. | 다중-사슬 키메라 폴리펩티드 및 이의 용도 |
| CN112168971B (zh) * | 2019-07-03 | 2023-04-04 | 义慧科技(深圳)有限公司 | 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| WO2021158110A1 (en) * | 2020-02-07 | 2021-08-12 | Biorion Technologies B.V. | Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| KR20230031280A (ko) | 2020-06-01 | 2023-03-07 | 에이치씨더블유 바이올로직스, 인크. | 노화 관련 장애의 치료 방법 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| MX2023014109A (es) * | 2021-05-28 | 2024-01-17 | Xyone Therapeutics Inc | Constructos de anticuerpos multiespecificos contra dominio extracelular/muc1-c (muc1-c/ecd). |
| WO2023056243A1 (en) * | 2021-09-29 | 2023-04-06 | Dragonfly Therapeutics, Inc. | Antibodies targeting baff-r and use thereof |
| CN119110809A (zh) * | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| JP2025508939A (ja) | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| JP2025529898A (ja) * | 2022-08-25 | 2025-09-09 | ブライト バイオロジクス リミテッド ライアビリティ カンパニー | 多重特異的抗体及びその使用 |
| CN119143837B (zh) * | 2023-04-18 | 2025-10-28 | 中国海洋大学 | Xo抑制肽agdy及其应用 |
| CN119930817B (zh) * | 2024-12-24 | 2025-12-02 | 国科大杭州高等研究院 | Tigit全人源抗体及其制备方法与应用 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK368882A (da) | 1981-08-25 | 1983-02-26 | Alan John Kingsman | Expessions vektorer |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
| US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| EP0184576B1 (en) | 1984-12-06 | 1990-06-27 | Fina Research S.A. | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5268358A (en) * | 1988-12-08 | 1993-12-07 | Cor Therapeutics, Inc. | PDGF receptor blocking peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
| EP0584082B1 (en) * | 1991-01-31 | 2000-05-31 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
| AU2861692A (en) * | 1991-10-18 | 1993-05-21 | Beth Israel Hospital Association, The | Vascular permeability factor targeted compounds |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5817310A (en) * | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
| US20020009443A1 (en) * | 1991-12-02 | 2002-01-24 | Vanitha Ramakrishman | Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
| EP0749319A1 (en) | 1992-09-14 | 1996-12-27 | Pfizer Inc. | Immortalized cells and uses therefor |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5641655A (en) | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
| US5654173A (en) | 1996-08-23 | 1997-08-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
| US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| CN1230997A (zh) | 1996-07-17 | 1999-10-06 | 津莫吉尼蒂克斯公司 | 甲醇毕赤酵母的转化 |
| ES2236634T3 (es) * | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20070059302A1 (en) * | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN1402733A (zh) * | 1999-06-03 | 2003-03-12 | 人体基因组科学有限公司 | 血管生成蛋白及其应用 |
| WO2001090192A2 (en) * | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| EP1490483B1 (en) | 2001-04-19 | 2015-06-03 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| ATE430580T1 (de) * | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040018557A1 (en) * | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| KR101228124B1 (ko) * | 2002-06-14 | 2013-01-31 | 이뮤노메딕스, 인코오포레이티드 | 단클론 항체 pam4 및 췌장암의 진단 및 치료를 위한이들의 용도 |
| AU2003267967B2 (en) | 2002-06-18 | 2008-11-20 | Zymogenetics, Inc. | Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| JP4818917B2 (ja) | 2003-08-08 | 2011-11-16 | イミューノメディクス、インコーポレイテッド | 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体 |
| PL1660057T3 (pl) * | 2003-08-27 | 2012-10-31 | Ophthotech Corp | Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej |
| MXPA06003163A (es) | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
| US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| KR20080090441A (ko) | 2005-12-21 | 2008-10-08 | 메디뮨 엘엘씨 | Epha2 bite 분자 및 이의 용도 |
| WO2007140534A1 (en) * | 2006-06-08 | 2007-12-13 | Csl Limited | Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| JP2010518839A (ja) | 2007-02-21 | 2010-06-03 | アブリンクス エン.ヴェー. | 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び/もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド |
| BRPI0810374A2 (pt) | 2007-04-17 | 2014-10-29 | Imclone Llc | Inibidores específicos do pdgfrbeta |
| CA2702637A1 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
-
2009
- 2009-03-27 EP EP13159556.3A patent/EP2604280A3/en not_active Withdrawn
- 2009-03-27 EP EP13159549.8A patent/EP2604279A1/en not_active Withdrawn
- 2009-03-27 AU AU2009228158A patent/AU2009228158B2/en not_active Ceased
- 2009-03-27 PL PL09724060T patent/PL2274008T3/pl unknown
- 2009-03-27 EP EP09724060.0A patent/EP2274008B1/en active Active
- 2009-03-27 WO PCT/US2009/038495 patent/WO2009120922A2/en not_active Ceased
- 2009-03-27 DK DK09724060.0T patent/DK2274008T3/da active
- 2009-03-27 CA CA2716882A patent/CA2716882A1/en not_active Abandoned
- 2009-03-27 PT PT97240600T patent/PT2274008E/pt unknown
- 2009-03-27 US US12/934,756 patent/US9441034B2/en active Active
- 2009-03-27 HR HRP20140244AT patent/HRP20140244T1/hr unknown
- 2009-03-27 ES ES09724060.0T patent/ES2456296T3/es active Active
- 2009-03-27 JP JP2011502087A patent/JP5425180B2/ja not_active Expired - Fee Related
- 2009-03-27 SI SI200930882T patent/SI2274008T1/sl unknown
-
2010
- 2010-08-15 IL IL207618A patent/IL207618A/en active IP Right Grant
-
2013
- 2013-11-26 JP JP2013244129A patent/JP5855627B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-23 CY CY20141100361T patent/CY1115382T1/el unknown
- 2014-05-27 AU AU2014202867A patent/AU2014202867B2/en not_active Ceased
- 2014-11-11 IL IL235618A patent/IL235618A/en active IP Right Grant
- 2014-11-11 IL IL235619A patent/IL235619A/en not_active IP Right Cessation
-
2015
- 2015-12-09 JP JP2015240210A patent/JP6140796B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-11 US US15/207,428 patent/US9708390B2/en active Active
- 2016-12-14 AU AU2016273894A patent/AU2016273894A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518546A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| HRP20140244T1 (hr) | Sastavi i metode za inhibiranje pdgfrbeta i vegf-a | |
| JP2020531048A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| CN115003333A (zh) | Pvrig结合蛋白及其医药用途 | |
| JP2019533989A5 (ja) | 抗pd−1抗体及びその使用 | |
| JP2018534933A5 (enExample) | ||
| JP2015533853A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2013538553A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| JP2014531201A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| JP2010507594A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2009297037A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| JP2018536632A5 (ja) | B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子 |